Efficacy and safety of tamsulosin for benign prostatic hyperplasia: Clinical experience in the primary care setting

Current Medical Research and Opinion

Volumn 22, Issue 4, 2006, Pages 721-730

  Flannery, Michael T ^a   Ramsdell, Joe ^b   Ranhosky, Alan ^c   Davidai, Giora ^c   Ruoff, Gary ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d Westside Family Medical Center   (United States)

Author keywords

Blocker; Benign prostatic hyperplasia; Primary care setting; Tamsulosin

Indexed keywords

ACETYLSALICYLIC ACID; CETIRIZINE; FEXOFENADINE; LORATADINE; PARACETAMOL; PRAZOSIN; TAMSULOSIN;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NOCTURIA; PAIN; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PHYSICIAN; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; SYMPTOM; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; UROLOGY; VITAL SIGN;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33646231008     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X96443     Document Type: Article

References (26)

1. 1A-adrenergic antagonist. Urology 1998;51:861-72
2. Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995;46(Suppl 3A):41-6
3. Flannery MT. Efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia (BPH): clinical experience in the primary care setting. J Am Geriatr Soc 2001;49:S85 [abstract P229]
4. McSherry J, Weiss R. Managing benign prostatic hyperplasia in primary care: patient-centered approach. Can Fam Physician 2000;46:383-9
5. Scott-Levin. Physician drug and diagnosis audit, 2000
6. Fawzy A, Fontenot C, Guthrie R, et al. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med 1997;29:321-5
7. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-7
8. Narayan P, Djavan B. Prospective, randomized multicenter trial of tamsulosin vs terazosin to evaluate the velocity of the onset of action. J Urol 2002;167:376 [abstract 1497]
9. Lepor H; for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900
10. Lepor H; for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998;51:901-6
11. Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 2000;34:188-99
12. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65:215-28
13. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393-4
14. Barry MJ, Fowler Jr FJ, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992;148:1549-57
15. Barry MJ, Fowler Jr FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995;33(Suppl):AS145-55
16. Hollander M, Wolfe DA. The one-sample location problem. In: Hollander M, Wolfe DA, editors. Nonparametric statistical methods. New York: John Wiley & Sons; 1973. p. 26-66
17. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J 1995;310:170
18. Narayan P, Tewari A; members of United States 93-01 Study Group. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998;160:1701-6
19. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170:498-502
20. Schulman CC, Cortvriend J, Jonas U, et al.; on behalf of the European Tamsulosin Study Group. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol 1999;36:609-20
21. Alfuzosin® hydrochloride (uroxatral) prescribing information. New York (NY): Sanofi-Synthelabo; June 2003
22. de Mey C, Michel MC, McEwen J, et al. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998;33:481-8
23. 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606-11
24. Fawzy A, Braun K, Lewis GP, et al.; for the Multicenter Study Group. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995;154:105-9
25. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2000;283:1967-75
26. Tewari A, Narayan P. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Urology 1999;53(Suppl 3A):14-20